SFDA organized a workshop entitled: ” Licensing and Registration of non- pharmaceutical Feed Additives Organizations and Products” at Jeddah Chamber of Commerce.

Based on the Drug Sector efforts at SFDA to update the guidelines continuously, updates were made on the Regulatory Framework of Drug Approvals and Guidance for Submission. A release note is provided to clarify the differences between the old and new versions.

The new updates of the Regulatory Framework of Drug Approvals are:H1

SFDA, represented by Drug Sector, organized Drug Awareness Program “ one of the Sector’s programs”- in order to increase the public awareness of the adverse effects of using drugs. The sector continued to organize its social activities in a number of  Commercial Centers in Riyadh. The purpose of the program is to increase the public awareness, to clarify the risks of drug misuse and ignoring the instructions for drug use, in addition to introduction of SFDA’s mandate.

SFDA announced that the news communicated on the social media about the recall of vitamin D ‘ One Alpha’  produced by Leo company of Denmark , is not true. However,  no new issues regarding the safety of the product, when used properly, or regarding its quality mandating its recall from the Saudi market.

The activities of The Drug Awareness Caravan, organized by SFDA, has recently concluded it 6th, cycle at Mahayl Assir, Al Majardah & Ballasmar hospitals.

Under the auspice of H.E. the Chief Executive Officer of SFDA, Dr. Mohammed bin Ahmed Al Kanhal, SFDA’s Drug Sector held its 2nd, Annual Gathering on Tuesday 19/2/1434H ( 1/1/2013) at ‘ Bin Turki Hall’ , Riyadh Sheraton Hotel for the sector’s employees, for the year 1433l2012

  SFDA, represented by Drug Sector won the First Place of Health Awareness Committee ‘Hayatuna’ “Innovation in Health Awareness” Award, in Health Awareness Publications.

The Saudi food & drug authority (represented by the department of pricing and pharmaceutical-economic at drug sector) participated in the first Saudi conference for pharmaceutical-economic which was held on the 3-4 of Rajb 1432H (5-6 June 2011) at the Intercontinental Hotel. This conference was organized by the King Saud Medical City under the Ministry of Health and in presence of his highness Dr. Andullah Alrabeeah the Health Minister.

Recently, the French Medicine Agency has suspended marketing authorization of anti-diabetic drug Pioglitazone (Actos®). French agency action has been announced after the result of recent retrospective cohort study has become available. This study was carried out in France and suggested an excess increase in bladder cancer among pioglitazone and pioglitazone-containing product users, Adjusted Hazard Ration (HR) was (1.22 [95% CI: 1.05-1.43]).

The SFDA announced that the duty of monitoring drugs will be
 transferred from the Ministry of health to the SFDA on
Wednesday, 15\7\1430 that equals 8\7\2009.

His Excellency Dr. Saleh Abdullah Bawazeer, Vice Executive
 President of Drug Affairs, clarified that by this process we apply
 the SFDA system which includes transferring all regulative,
 executive and monitoring duties, that are related to drugs, to the
 SFDA.